Apolipoprotein B: Why Particle Count Is Changing How We Measure Heart Risk

If you've ever had a cholesterol test, you probably got a number for your total cholesterol and maybe your LDL cholesterol. Your GP looked at it, compared it to the guidelines, and told you whether it was fine or not.

For most people, that's enough. Standard cholesterol testing works well at a population level, and your GP is following NICE guidelines that are designed to be both clinically effective and cost-efficient for the NHS. But for certain groups of patients, the standard metrics can miss something important. That's where Apolipoprotein B comes in.

What Is Apolipoprotein B?

Apolipoprotein B (ApoB) is a protein found on the surface of every lipoprotein particle that can damage your arteries. Each atherogenic particle carries exactly one molecule of ApoB, which makes measuring ApoB a direct way to estimate the total number of potentially harmful particles circulating in your blood [Sniderman et al., 2019].

That includes LDL particles (the ones most people know about), but also VLDL, IDL, and lipoprotein(a) particles. Standard cholesterol testing measures the mass of cholesterol carried inside these particles. ApoB measures the molar concentration of the particles themselves, which serves as a direct proxy for particle number.

Boats on the Road: Why Particle Count Matters

Think of your bloodstream as a motorway. The lipoprotein particles are the vehicles, and the cholesterol they carry is the cargo. Standard testing tells you how much cargo is on the road. ApoB tells you how many vehicles are driving.

The distinction matters because arterial damage isn't caused by the weight of cholesterol floating past. It's caused by individual particles embedding themselves in the arterial wall. More particles means more collisions with the wall, more entrapment, and more plaque formation over time. Two people can have identical LDL cholesterol, but the one with more, smaller, denser particles has a higher risk because they have more "vehicles" hitting the arterial walls.

The Discordance Problem

For most healthy people, LDL cholesterol and ApoB tell a similar story. But in certain clinical situations, the two diverge. This is called discordance, and it's particularly common in people with:

• Type 2 diabetes or insulin resistance

• Metabolic syndrome or central obesity

• High triglycerides

• A family history of premature cardiovascular disease

• Patients already on statin therapy where residual risk needs reassessing

In these groups, insulin resistance and altered lipid metabolism tend to produce large numbers of small, dense LDL particles. Each particle carries less cholesterol, so the total mass (LDL-C) can look reassuringly normal while the actual particle count (reflected by ApoB) is elevated. A 2025 systematic review of over 593,000 participants found that when LDL-C and ApoB disagree, cardiovascular outcomes consistently track with the ApoB value, not the LDL-C [Bray et al., 2025].

The mechanism is worth understanding. When triglycerides are elevated, the liver produces more VLDL particles, which are then remodelled in the bloodstream into smaller, cholesterol-depleted LDL particles. These smaller particles are more numerous but carry less cholesterol per particle. On a standard lipid panel, the total low density cholesterol cargo (LDL-C) may look acceptable. But the number of particles bouncing off your arterial walls has increased substantially. On top of this, elevated triglycerides also increase the concentration of remnant cholesterol, which refers to the cholesterol carried by VLDL and IDL particles. Remnant cholesterol is increasingly recognised as an independent contributor to atherosclerosis, and it's captured by ApoB but entirely invisible to a standard LDL-C measurement.

UK Biobank data from over 41,000 adults confirmed this pattern, showing that ApoB predicted major adverse cardiovascular events more reliably than LDL-C, with risk becoming statistically significant at as little as 2% discordance between the two measures [Epstein et al., 2025].

What Do the Guidelines Say?

There's an important distinction between what UK guidelines currently recommend and what international cardiovascular societies are moving toward.

NICE uses non-HDL cholesterol as its primary lipid target. This is a pragmatic decision: once you've measured total cholesterol and HDL, calculating non-HDL-C is essentially free, and for most of the population it's a reasonable proxy for particle burden. Your GP isn't missing anything by following this approach for the general population.

However, the 2019 ESC/EAS guidelines (the European cardiology guidelines) give ApoB a Class I recommendation, specifically for patients with diabetes, obesity, metabolic syndrome, or very high triglycerides [Mach et al., 2019]. In these patients, they recommend using ApoB instead of LDL-C to guide treatment intensity.

The 2024 National Lipid Association (NLA) Expert Consensus went further, arguing that ApoB should be considered a primary tool for cardiovascular risk assessment [Soffer et al., 2024].

ApoB Target Levels

The following thresholds are derived from the 2024 NLA Expert Consensus and the 2019 ESC/EAS guidelines. They are intended to inform clinical discussion with your doctor, not to replace a formal cardiovascular risk assessment such as QRISK3.

• Below 90 mg/dL (0.90 g/L) is generally considered desirable for the population at low to moderate cardiovascular risk

• Below 70 mg/dL (0.70 g/L) is the target suggested by ESC/EAS for individuals assessed by their clinician as being at high cardiovascular risk

• Below 60 mg/dL (0.60 g/L) is the target for individuals assessed as very high risk (for example, those with established cardiovascular disease or familial hypercholesterolaemia)

Your cardiovascular risk category is determined by your doctor based on a combination of factors including age, sex, blood pressure, smoking status, diabetes status, and family history. An ApoB number on its own doesn't tell you your risk category.

No Fasting Required

One practical advantage of ApoB is that it doesn't require fasting. Standard lipid panels can be affected by recent meals, particularly triglyceride levels. ApoB remains stable regardless of when you last ate [Nordestgaard et al., 2016], making it a more convenient and consistent marker.

When to See Your GP

An ApoB test is a screening tool, not a cardiovascular diagnosis. If your result is above the desirable range, the next step is sharing it with your GP, not making treatment decisions on your own.

Your GP will evaluate your ApoB result alongside your full cardiovascular risk profile, typically using QRISK3, which accounts for age, sex, blood pressure, smoking status, kidney function, and family history. That overall risk score determines whether medication, lifestyle changes, or monitoring is the right approach.

You should see your GP promptly if you have chest pain, unexplained breathlessness on exertion, or a strong family history of heart attacks before age 55 in male relatives or 65 in female relatives. These situations need clinical assessment first.

How Brooksby Medical Can Help

Brooksby Medical offers a single Apolipoprotein B test or it is available in two of our blood test profiles Advanced Lipid profile and Advanced Heart and Vascular Risk Profile

Every Brooksby report is written personally by a GP who explains what your results mean in context. If your ApoB is elevated, we'll recommend sharing your report with your NHS GP so they can incorporate it into your cardiovascular risk assessment and determine the right next steps.

References

1. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455

2. Soffer DE, Stulc T, Engelen L, et al. National Lipid Association Expert Consensus: ApoB as a primary marker. J Clin Lipidol. 2024. NLA 2024 Consensus

3. Bray JK, et al. ApoB and cardiovascular outcomes in discordance: a systematic review and meta-analysis. 2025. 593,000+ participants. Bray et al., 2025

4. Epstein SE, et al. Apolipoprotein B and cardiovascular risk in UK Biobank: discordance analysis. 2025. 41,000+ adults. Epstein et al., 2025

5. Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. 2019;4(12):1287-1295. doi:10.1001/jamacardio.2019.3780

6. Thanassoulis G, Williams K, Bhatt DL. Absolute risk reduction per unit decrease in ApoB. Lancet. 2023. Thanassoulis et al., 2023

7. Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not routinely required for lipid testing. Eur Heart J. 2016;37(25):1944-1958. doi:10.1093/eurheartj/ehw152

8. British Heart Foundation. Heart and circulatory disease statistics 2024. BHF Statistics

Written by Dr James Coleman, GP and founder of Brooksby Medical. Dr Coleman is a practising General Practitioner who founded Brooksby Medical to give patients direct access to the blood tests and clinical interpretation they need, without waiting lists.

Medically reviewed: March 2026 | Next review due: March 2027

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Blood test results should always be interpreted by a qualified healthcare professional in the context of your individual symptoms, medical history, and clinical picture. If you have concerns about your health, please consult your GP.